Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$38.20 USD

38.20
196,260

-0.17 (-0.44%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (49 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SurModics (SRDX) Beats Q2 Earnings Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 3.33% and -0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neogen (NEOG) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance in both its Animal Safety and Food Safety segments during the fiscal third quarter pushes Neogen (NEOG) to a 52-week high.

    Here's Why You Should Hold NextGen (NXGN) in Your Portfolio

    by Zacks Equity Research

    Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.

      Merck KGaA Chooses PRA Health's (PRAH) Remote Monitoring Tool

      by Zacks Equity Research

      PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.

      PAHC or SRDX: Which Is the Better Value Stock Right Now?

      by Zacks Equity Research

      PAHC vs. SRDX: Which Stock Is the Better Value Option?

      BD's (BDX) $65M Investment to Boost Supply-Chain Strength

      by Zacks Equity Research

      BD's (BDX) $65-million investment in constructing an advanced facility will become integral to the U.S. medical device supply chain.

      Here's Why You Should Retain Luminex (LMNX) Stock for Now

      by Zacks Equity Research

      Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.

      Sriparna Ghosal headshot

      Buy 3 MedTech Stocks That Are Outperforming S&P 500 in 2021

      by Sriparna Ghosal

      Let's take a look at the three MedTech stocks performing well lately, banking on a host of impressive developments.

      Here's Why You Should Hold on to Ecolab (ECL) Stock for Now

      by Zacks Equity Research

      Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.

      BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test

      by Zacks Equity Research

      BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.

      PerkinElmer's (PKI) Horizon Discovery Broadens Portfolio

      by Zacks Equity Research

      PerkinElmer's (PKI) CRISPRi will help scientists get a firmer foothold in the biological pathways, processes and pathologies of disease.

      Why You Should Add Surmodics (SRDX) to Your Portfolio Now

      by Zacks Equity Research

      Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.

      Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

      by Zacks Equity Research

      Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.

      SurModics (SRDX) Beats Q1 Earnings Estimates

      by Zacks Equity Research

      SurModics (SRDX) delivered earnings and revenue surprises of 133.33% and -3.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

      Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

      by Zacks Equity Research

      SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?

      by Zacks Equity Research

      PAHC vs. SRDX: Which Stock Is the Better Value Option?

      Why Is SurModics (SRDX) Up 6.4% Since Last Earnings Report?

      by Zacks Equity Research

      SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates

      by Zacks Equity Research

      Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.

      SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      SurModics (SRDX) delivered earnings and revenue surprises of -1900.00% and 4.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

      Earnings Preview: SurModics (SRDX) Q4 Earnings Expected to Decline

      by Zacks Equity Research

      SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Earnings Preview: SurModics (SRDX) Q4 Earnings Expected to Decline

      by Zacks Equity Research

      SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      NUVA or SRDX: Which Is the Better Value Stock Right Now?

      by Zacks Equity Research

      NUVA vs. SRDX: Which Stock Is the Better Value Option?

      Here's Why You Should Retain OPKO Health (OPK) Stock for Now

      by Zacks Equity Research

      Investor confidence is high on OPKO Health (OPK), thanks to solid prospects.

      Thermo Fisher Rides on End Market Growth, Test Revenues

      by Zacks Equity Research

      Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.

      Veeva Collaborates With RedHill for Coronavirus Clinical Study

      by Zacks Equity Research

      RedHill has adopted Veeva's (VEEV) Vault CDMS platform for the opaganib study.